ScripAtsena Therapeutics thinks it can be a success story in the gene therapy field, where some companies have recently stumbled, with the closure of a funding round that it plans to use especially for its
ScripPfizer’s recent exit from gene therapies was not an indictment of the safety and efficacy of gene and cellular therapies. Rather it was the latest example of the difficulties in commercializing these
Pink SheetUS Centers for Medicare and Medicaid Services Administrator nominee Mehmet Oz is committed to defending the Medicare price negotiation program, but will pursue other ways to lower drug costs if confir
ScripBristol Myers Squibb is moving to take over its longtime cell therapy partner 2seventy bio and the CAR-T cell therapy they developed and commercialized together, Abecma (idecabtagene vicleucel). The b